Main Emphasis of a Statistician's Work in the Pharmaceutical Industry--Section 1: Late-stage Clinical Trial Design

Speaker: Deli Wang 2024 Nov 8, 2024 02:00 PM EST

Registration link:

https://us06web.zoom.us/webinar/register/WN_89sUMD6uT4WEqaDVfzcqlA#/registration

About the Webinar

The objectives of this webinar are to provide detailed information for standard late-stage clinical trials design and understand main components for the sample size determination for late-stage clinical trials. The study design will focus on Phase 2 and Phase 3 trial designs for continuous, binary or time-to-event endpoints. Parameters needed for the sample size determination for clinical trials are discussed and separate examples will be used to demonstrate how to calculate sample size for Phase 3 superiority trials with continuous endpoint, binary endpoint and time-to-event endpoint.

About the Speaker

Deli Wang Ph.D., MMed, is a Director of Statistics and Research Fellow in AbbVie Inc. He obtained his Ph.D. in Biostatistics in 2004 from the University of Iowa, USA. His medical training in Beijing Medical University in China (currently is Peking University Health Service Center) and statistical expertise give him a unique perspective for the drug development. He is currently the statistical lead in new drug development for neurodegenerative diseases including Alzheimer's disease and ALS. He has experience in design and conduct of Phase 2 and 3 clinical trials in multiple therapeutic areas such as neurology, psychiatry, oncology, nephrology, and immunology. He is active in statistical methodology research and published statistical methodology papers/book chapter on interim Go/No-Go decision-making methodology, multiplicity adjustment, and statistical methodology to demonstrate disease modification in neurodegenerative disease clinical trials. He authored over 70 peer reviewed papers/book chapter.